Melpomene Prostate cancer can usually be clinically cured with standard treatment in its early stages. Early-stage prostate cancer mainly means that the tumor is limited to the prostate capsule without lymph node metastasis or distant metastasis. Through comprehensive means such as radical surgical resection, radiotherapy or endocrine therapy, the disease can be effectively controlled or even completely eliminated. The treatment effect of early-stage prostate cancer is better, and the 10-year survival rate is higher.
Localized prostate cancer can be completely eliminated through radical prostatectomy, and postoperative radiotherapy can further reduce the risk of recurrence. For low- and medium-risk patients, active monitoring is also a reasonable option, and doctors will determine the timing of subsequent intervention based on the progression of the disease. In radiotherapy, both external beam radiotherapy and brachytherapy can accurately kill cancer cells, and modern technology has greatly reduced the damage to surrounding tissues.
A very small number of high-risk early-stage patients may have micrometastases and require adjuvant endocrine therapy for 2-3 years to inhibit cancer cell growth. In this case, prostate-specific antigen levels need to be tested regularly and the condition monitored with imaging examinations. If biochemical recurrence occurs, timely salvage radiotherapy or systemic treatment can still achieve a good prognosis.
Urology and oncologists should evaluate the staging as soon as possible after diagnosis and develop a personalized plan. After treatment, prostate-specific antigen needs to be reviewed every 3-6 months, maintaining a low-fat and high-fiber diet, and regular aerobic exercise such as brisk walking can help improve the prognosis. Avoid long-term cycling that puts pressure on the perineum. Supplement vitamin D appropriately but not excessively.
